Altimmune (MEX:ALT1) Loans Receivable: MXN0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ALT1 Altimmune Inc MEX:ALT1
28 GF Score
Price MXN48.50
GF Value MXN5.37
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Altimmune Loans Receivable?

Altimmune MEX:ALT1 28 Loans Receivable is MXN0.00 Mil as of Mar. 2026. GuruFocus rates MEX:ALT1 with a GF Score™ of 28/100 and a GF Value™ of MXN5.37 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Altimmune's Loans Receivable for the quarter that ended in Mar. 2026 was MXN0.00 Mil.

Altimmune Loans Receivable Historical Data

* Premium members only.

The historical data trend for Altimmune's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Loans Receivable Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Altimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ALT1
28GF Score
Altimmune Inc MEX:ALT1
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Altimmune Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of MXN0.00 Mil mean?
Altimmune (MEX:ALT1) has a Loans Receivable of MXN0.00 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Altimmune and its competitors.
Is Altimmune's Loans Receivable too high?
Altimmune's current Loans Receivable is MXN0.00 Mil. Overall, Altimmune has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Altimmune's Loans Receivable compare to VSTM and PRME?
Altimmune's Loans Receivable of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Altimmune and its competitors. Altimmune's current Loans Receivable is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Based on GuruFocus' analysis, Altimmune (MEX:ALT1) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN5.37, compared to a current price of MXN48.50 — trading 803.2% above its estimated fair value. The current Loans Receivable is MXN0.00 Mil. Altimmune's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Altimmune (MEX:ALT1), the current Loans Receivable is MXN0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Altimmune (MEX:ALT1) Overvalued in 2026?

Based on GuruFocus' analysis, Altimmune stock appears to be overvalued. The current stock price of MXN48.50 is trading 803.2% above its estimated GF Value™ of MXN5.37. GuruFocus considers Altimmune to be Significantly Overvalued.

Key valuation signals for MEX:ALT1:

  • Loans Receivable: MXN0.00 Mil
  • GF Value™: MXN5.37 vs. price of MXN48.50 (803.2% above fair value)
  • GF Score™: 28/100 with 2 warning signs

No single metric tells the full story. See the MEX:ALT1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Altimmune Business Description

Other Exchanges ALT:USA0A4C:UK3G0:Germany
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
28GF Score

Get the complete analysis for MEX:ALT1

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.50
Price
MXN5.37
GF Value